利拉鲁肽对二甲双胍控制不佳的2型糖尿病非酒精性脂肪肝的疗效观察

The Effect of Liraglutide on Type 2 Diabetes Mellitus with Non-Alcoholic Fatty Liver Inadequately Controlled by Metformin

观察利拉鲁肽对二甲双胍控制不佳的2型糖尿病(Type 2 diabetes mellitus,T2DM)合并非酒精性脂肪肝(Non-alcoholic fatty liver disease,NAFLD)患者的疗效和安全性。选取含二甲双胍方案治疗3个月以上且效果不佳的2型糖尿病伴NAFLD患者34例,通过自身对照,观察加用利拉鲁肽1.8 mg/d,4~6个月后临床指标变化。经加用利拉鲁肽治疗后,患者体重指数(BMI),空腹血糖(FPG),2 h餐后血糖(2h PBG),糖化血红蛋白(Hb A1c),稳态模型指数(HOMA-IR),血浆总胆固醇(TC)和甘油三酯(TG)均显著下降,肝脾CT比值上升,脂肪肝严重程度得到缓解,临床不良反应轻微。利拉鲁肽对二甲双胍控制不佳的T2DM合并NAFLD患者具有良好的临床疗效。

The purpose is to investigate the clinical effect of Liraglutideon T2DM with NAFLD inadequately controlled by metformin.The clinical data of 34 patients who were treated with Liraglutide were analyzed.After 4 to 6 months treatment,body mass index（BMI）,fasting plasma glucose（FPG）,2 hours postprandial blood glucose（2 hPBG）,glycosylated hemoglobin（HbAlc）,homeostasis model assessment of insulin resistance index（HOMA-IR）,total cholesterol（TC） and triglyceride（TG） were decreased significantly,and liver/spleen ratios were increased significantly,which prevented progression of NAFLD.Liraglutide can be beneficial to patients of T2DM with NAFLD inadequately controlled by metformin.